Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 168905, 14 pages
http://dx.doi.org/10.1155/2015/168905
Review Article

Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease

Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center, 6423906 Tel Aviv, Israel

Received 24 October 2014; Revised 27 January 2015; Accepted 4 February 2015

Academic Editor: Fabio Galvano

Copyright © 2015 Liane Rabinowich and Oren Shibolet. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Fontana, “Acute liver failure including acetaminophen overdose,” Medical Clinics of North America, vol. 92, no. 4, pp. 761–794, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Larrey, “Epidemiology and individual susceptibility to adverse drug reactions affecting the liver,” Seminars in Liver Disease, vol. 22, no. 2, pp. 145–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. S. Björnsson, O. M. Bergmann, H. K. Björnsson, R. B. Kvaran, and S. Olafsson, “Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland,” Gastroenterology, vol. 144, no. 7, pp. 1419–1425, 2013. View at Google Scholar · View at Scopus
  4. M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994,” American Journal of Epidemiology, vol. 178, no. 1, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, “Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study,” Hepatology, vol. 42, no. 1, pp. 44–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. L. White, F. Kanwal, and H. B. El-Serag, “Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review,” Clinical Gastroenterology and Hepatology, vol. 10, no. 12, pp. 1342.e2–1359.e2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Grieco, A. Forgione, L. Miele et al., “Fatty liver and drugs,” European Review for Medical and Pharmacological Sciences, vol. 9, no. 5, pp. 261–263, 2005. View at Google Scholar · View at Scopus
  9. G. Danan and C. Benichou, “Causality assessment of adverse reactions to drugs—I: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries,” Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1323–1330, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Benichou, G. Danan, and A. Flahault, “Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge,” Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1331–1336, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Publisher · View at Google Scholar · View at Scopus
  12. V. A. J. Maria and R. M. M. Victorino, “Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis,” Hepatology, vol. 26, no. 3, pp. 664–669, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999. View at Google Scholar · View at Scopus
  15. E. M. Brunt, C. G. Janney, A. M. di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” The American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. D. E. Kleiner, E. M. Brunt, M. van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. E. Kleiner, N. P. Chalasani, W. M. Lee et al., “Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations,” Hepatology, vol. 59, no. 2, pp. 661–670, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. J. Andrade, M. I. Lucena, M. C. Fernandez et al., “Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period,” Gastroenterology, vol. 129, no. 2, pp. 512–521, 2005. View at Publisher · View at Google Scholar
  19. D. E. Kleiner, “The pathology of drug-induced liver injury,” Seminars in Liver Disease, vol. 29, no. 4, pp. 364–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Zhang, J. Ouyang, and S. N. Thung, “Histopathologic manifestations of drug-induced hepatotoxicity,” Clinics in Liver Disease, vol. 17, no. 4, pp. 547–564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Ramachandran and S. Kakar, “Histological patterns in drug-induced liver disease,” Journal of Clinical Pathology, vol. 62, no. 6, pp. 481–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. W. Guglielmi, D. Boggio-Bertinet, A. Federico et al., “Total parenteral nutrition-related gastroenterological complications,” Digestive and Liver Disease, vol. 38, no. 9, pp. 623–642, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Sahoo and J. Hart, “Hstopathological features of L-asparaginase-induced liver disease,” Seminars in Liver Disease, vol. 23, no. 3, pp. 295–299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Freneaux, G. Labbe, P. Letteron et al., “Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic,” Hepatology, vol. 8, no. 5, pp. 1056–1062, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kimura, T. Kobayashi, Y. Tanaka, and Y. Sasaki, “Liver histopathology in clinical Reye syndrome,” Brain and Development, vol. 13, no. 2, pp. 95–100, 1991. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Lettéron, N. Brahimi-Bourouina, M.-A. Robin, A. Moreau, G. Feldmann, and D. Pessayre, “Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid β-oxidation,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 272, 1, no. 5, pp. G1141–G1150, 1997. View at Google Scholar · View at Scopus
  27. E. Freneaux, B. Fromently, A. Berson et al., “Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids,” Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 2, pp. 529–535, 1990. View at Google Scholar · View at Scopus
  28. I. R. Wanless, S. Dore, N. Gopinath et al., “Histopathology of cocaine hepatotoxicity. Report of four patients,” Gastroenterology, vol. 98, no. 2, pp. 497–501, 1990. View at Google Scholar · View at Scopus
  29. F. Zhao, P. Xie, J. Jiang, L. Zhang, W. An, and Y. Zhan, “The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro,” International Journal of Molecular Sciences, vol. 15, no. 3, pp. 4019–4030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. O. A. Gudbrandsen, T. H. Rost, and R. K. Berge, “Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver,” Journal of Lipid Research, vol. 47, no. 10, pp. 2223–2232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. P. Vitins, A. S. Kienhuis, E. N. Speksnijder, M. Roodbergen, M. Luijten, and L. T. M. van der Ven, “Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models,” Archives of Toxicology, vol. 88, no. 8, pp. 1573–1588, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Anthérieu, A. Rogue, B. Fromenty, A. Guillouzo, and M.-A. Robin, “Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells,” Hepatology, vol. 53, no. 6, pp. 1895–1905, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. L. K. Cole, R. L. Jacobs, and D. E. Vance, “Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis,” Hepatology, vol. 52, no. 4, pp. 1258–1265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Zelber-Sagi, F. Salomone, H. Yeshua et al., “Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease,” Liver International, vol. 34, no. 6, pp. e128–e135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Fromenty, C. Fisch, G. Labbe et al., “Amiodarone inhibits the mitochondrial β-oxidation and fatty acids and produces microvesicular steatosis of the liver in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 3, pp. 1371–1376, 1990. View at Google Scholar · View at Scopus
  37. I. Larosche, P. Lettéron, B. Fromenty et al., “Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 2, pp. 526–535, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Berson, V. de Beco, P. Letteron et al., “Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes,” Gastroenterology, vol. 114, no. 4 I, pp. 764–774, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Dalaklioglu, G. E. Genc, N. H. Aksoy, F. Akcit, and S. Gumuslu, “Resveratrol ameliorates methotrexate-induced hepatotoxicity in rats via inhibition of lipid peroxidation,” Human and Experimental Toxicology, vol. 32, no. 6, pp. 662–671, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Jahovic, H. Çevik, A. Ö. Şehirli, B. Ç. Yeğen, and G. Şener, “Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats,” Journal of Pineal Research, vol. 34, no. 4, pp. 282–287, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Uraz, V. Tahan, C. Aygun et al., “Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity,” Digestive Diseases and Sciences, vol. 53, no. 4, pp. 1071–1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Çakir, E. Özkan, E. Dulundu et al., “Caffeic acid phenethyl ester (CAPE) prevents methotrexate-induced hepatorenal oxidative injury in rats,” Journal of Pharmacy and Pharmacology, vol. 63, no. 12, pp. 1566–1571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. A. Albukhari, H. M. Gashlan, H. A. El-Beshbishy, A. A. Nagy, and A. B. Abdel-Naim, “Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats,” Food and Chemical Toxicology, vol. 47, no. 7, pp. 1689–1695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. G. M. Suddek, “Protective role of thymoquinone against liver damage induced by tamoxifen in female rats,” Canadian Journal of Physiology and Pharmacology, vol. 92, no. 8, pp. 640–644, 2014. View at Publisher · View at Google Scholar
  45. I. Jafarian, M. R. Eskandari, V. Mashayekhi, M. Ahadpour, and M.-J. Hosseini, “Toxicity of valproic acid in isolated rat liver mitochondria,” Toxicology Mechanisms and Methods, vol. 23, no. 8, pp. 617–623, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Tong, X. W. Teng, T. K. H. Chang, and F. S. Abbott, “Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes,” Toxicological Sciences, vol. 86, no. 2, pp. 436–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Salomone, G. Li Volti, C. Rosso, G. Grosso, and E. Bugianesi, “Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis,” Journal of Gastroenterology and Hepatology, vol. 28, no. 7, pp. 1202–1208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. K. Tawfik, “Combination of coenzyme Q10 with methotrexate suppresses Freund's complete adjuvant-induced synovial inflammation with reduced hepatotoxicity in rats: effect on oxidative stress and inflammation,” International Immunopharmacology, vol. 24, no. 1, pp. 80–87, 2015. View at Publisher · View at Google Scholar
  49. S. Mukherjee, S. Ghosh, S. Choudhury et al., “Pomegranate reverses methotrexate-induced oxidative stress and apoptosis in hepatocytes by modulating Nrf2-NF-κB pathways,” Journal of Nutritional Biochemistry, vol. 24, no. 12, pp. 2040–2050, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Ali, S. Rashid, S. Nafees, S. K. Hasan, and S. Sultana, “Beneficial effects of Chrysin against Methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis,” Molecular and Cellular Biochemistry, vol. 385, no. 1-2, pp. 215–223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. I. S. Elefsiniotis, K. D. Pantazis, A. Ilias et al., “Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 6, pp. 593–598, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Biton, W. Mirza, G. Montouris, A. Vuong, A. E. Hammer, and P. S. Barrett, “Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy,” Neurology, vol. 56, no. 2, pp. 172–177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. J. I. T. Isojärvi, J. Rättyä, V. V. Myllylä et al., “Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy,” Annals of Neurology, vol. 43, no. 4, pp. 446–451, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Yilmaz, “Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?” Alimentary Pharmacology and Therapeutics, vol. 36, no. 9, pp. 815–823, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. G. N. Ioannou, W. G. Haigh, D. Thorning, and C. Savard, “Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis,” The Journal of Lipid Research, vol. 54, no. 5, pp. 1326–1334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Bruno, P. Maisonneuve, P. Castellana et al., “Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial,” British Medical Journal, vol. 330, no. 7497, pp. 932–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. R. N. Hardwick, C. D. Fisher, S. M. Street, M. J. Canet, and N. J. Cherrington, “Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis,” Drug Metabolism and Disposition, vol. 40, no. 3, pp. 450–460, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. R. N. Hardwick, J. D. Clarke, A. D. Lake et al., “Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis,” Toxicological Sciences, vol. 142, no. 1, pp. 45–55, 2014. View at Publisher · View at Google Scholar
  60. A. D. Lake, P. Novak, C. D. Fisher et al., “Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease,” Drug Metabolism and Disposition, vol. 39, no. 10, pp. 1954–1960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Vassallo and R. G. Trohman, “Prescribing amiodarone: an evidence-based review of clinical indications,” The Journal of the American Medical Association, vol. 298, no. 11, pp. 1312–1322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. A. E. Rätz Bravo, J. Drewe, R. G. Schlienger, S. Krähenbühl, H. Pargger, and W. Ummenhofer, “Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature,” Critical Care Medicine, vol. 33, no. 1, pp. 128–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Giannattasio, A. Salvio, M. Varriale, F. P. Picciotto, G. G. di Costanzo, and M. Visconti, “Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity,” Annali Italiani di Medicina Interna, vol. 17, no. 3, pp. 180–184, 2002. View at Google Scholar · View at Scopus
  64. A. Rhodes, J. B. Eastwood, and S. A. Smith, “Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?” Gut, vol. 34, no. 4, pp. 565–566, 1993. View at Publisher · View at Google Scholar · View at Scopus
  65. P. R. James and S. M. C. Hardman, “Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy,” Heart, vol. 77, no. 6, pp. 583–584, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. J. S. Kicker, J. A. Haizlip, and M. L. Buck, “Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant,” The Journal of Pediatric Pharmacology and Therapeutics, vol. 17, no. 2, pp. 189–195, 2012. View at Publisher · View at Google Scholar
  67. M. Nasser, T. R. Larsen, B. Waanbah, I. Sidiqi, and P. A. McCullough, “Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature,” Drug, Healthcare and Patient Safety, vol. 5, no. 1, pp. 191–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. J. J. Heger, E. N. Prystowsky, W. M. Jackman et al., “Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation,” The New England Journal of Medicine, vol. 305, no. 10, pp. 539–545, 1981. View at Publisher · View at Google Scholar · View at Scopus
  69. J. H. Lewis, R. C. Ranard, A. Caruso et al., “Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients,” Hepatology, vol. 9, no. 5, pp. 679–685, 1989. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Mattar, B. Juliar, I. Gradus-Pizlo, and P. Y. Kwo, “Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure,” Journal of Gastrointestinal and Liver Diseases, vol. 18, no. 4, pp. 419–423, 2009. View at Google Scholar · View at Scopus
  71. L. Llanos, R. Moreu, A. M. Peiró et al., “Causality assessment of liver injury after chronic oral amiodarone intake,” Pharmacoepidemiology and Drug Safety, vol. 18, no. 4, pp. 291–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Raja, S. N. Thung, M. I. Fiel, and C. Chang, “Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use,” Seminars in Liver Disease, vol. 29, no. 4, pp. 423–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Goldschlager, A. E. Epstein, G. V. Naccarelli et al., “A practical guide for clinicians who treat patients with amiodarone: 2007,” Heart Rhythm, vol. 4, no. 9, pp. 1250–1259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. L. C. C. Kum, W. W. L. Chan, H. H. Y. Hui et al., “Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction,” Clinical Cardiology, vol. 29, no. 7, pp. 295–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. J. H. Lewis, F. Mullick, K. G. Ishak et al., “Histopathologic analysis of suspected amiodarone hepatotoxicity,” Human Pathology, vol. 21, no. 1, pp. 59–57, 1990. View at Publisher · View at Google Scholar · View at Scopus
  76. S. R. Puli, M. A. Fraley, V. Puli, A. B. Kuperman, and M. A. Alpert, “Hepatic cirrhosis caused by low-dose oral amiodarone therapy,” The American Journal of the Medical Sciences, vol. 330, no. 5, pp. 257–261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. C.-C. Chang, M. Petrelli, J. F. Tomashefski Jr., and A. J. McCullough, “Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature,” Archives of Pathology and Laboratory Medicine, vol. 123, no. 3, pp. 251–256, 1999. View at Google Scholar · View at Scopus
  78. D. B. Jones, F. G. Mullick, J. H. Hoofnagle, and B. Baranski, “Reye's syndrome-like illness in a patient receiving amiodarone,” The American Journal of Gastroenterology, vol. 83, no. 9, pp. 967–969, 1988. View at Google Scholar · View at Scopus
  79. B. Rigas, L. E. Rosenfeld, K. W. Barwick et al., “Amiodarone hepatotoxicity. A clinicopathologic study of five patients,” Annals of Internal Medicine, vol. 104, no. 3, pp. 348–351, 1986. View at Publisher · View at Google Scholar · View at Scopus
  80. G. C. Farrell, “Drugs and steatohepatitis,” Seminars in Liver Disease, vol. 22, no. 2, pp. 185–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. J. F. Brien, S. Jimmo, F. J. Brennan, S. E. Ford, and P. W. Armstrong, “Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues,” Canadian Journal of Physiology and Pharmacology, vol. 65, no. 3, pp. 360–364, 1987. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Markos, M. E. Veronese, M. R. Nicholson, S. McLean, and J. E. Shevland, “Value of hepatic computerized tomographic scanning during amiodarone therapy,” The American Journal of Cardiology, vol. 56, no. 1, pp. 89–92, 1985. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Kaufmann, M. Török, A. Hänni, P. Roberts, R. Gasser, and S. Krähenbühl, “Mechanisms of benzarone and benzbromarone-induced hepatic toxicity,” Hepatology, vol. 41, no. 4, pp. 925–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. O. O. Oyetayo, C. E. Rogers, and P. O. Hofmann, “Dronedarone: a new antiarrhythmic agent,” Pharmacotherapy, vol. 30, no. 9, pp. 904–915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. S. H. Hohnloser, H. J. G. M. Crijns, M. van Eickels et al., “Effect of dronedarone on cardiovascular events in atrial fibrillation,” The New England Journal of Medicine, vol. 360, no. 7, pp. 668–678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. B. N. Singh, S. J. Connolly, H. J. G. M. Crijns et al., “Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter,” The New England Journal of Medicine, vol. 357, no. 10, pp. 987–999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. “In brief: FDA warning on dronedarone (Multaq),” The Medical Letter on Drugs and Therapeutics, vol. 53, no. 1359, p. 17, 2011.
  88. A. Felser, K. Blum, P. W. Lindinger, J. Bouitbir, and S. Krähenbühl, “Mechanisms of hepatocellular toxicity associated with dronedarone—a comparison to amiodarone,” Toxicological Sciences, vol. 131, no. 2, pp. 480–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Felser, A. Stoller, R. Morand et al., “Hepatic toxicity of dronedarone in mice: Role of mitochondrial β-oxidation,” Toxicology, vol. 323, pp. 1–9, 2014. View at Publisher · View at Google Scholar
  90. C. Perez, W. W. Sutow, Y. M. Wang, and J. Herson, “Evaluation of overall toxicity of high-dosage methotrexate regimens,” Medical and Pediatric Oncology, vol. 6, no. 3, pp. 219–228, 1979. View at Publisher · View at Google Scholar · View at Scopus
  91. R. K. Bath, N. K. Brar, F. A. Forouhar, and G. Y. Wu, “A review of methotrexate-associated hepatotoxicity,” Journal of Digestive Diseases, vol. 15, no. 10, pp. 517–524, 2014. View at Publisher · View at Google Scholar
  92. G. Schmajuk, Y. Miao, J. Yazdany, W. J. Boscardin, D. I. Daikh, and M. A. Steinman, “Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record,” Arthritis Care & Research, vol. 66, no. 8, pp. 1159–1166, 2014. View at Publisher · View at Google Scholar
  93. M. R. Fournier, J. Klein, G. Y. Minuk, and C. N. Bernstein, “Changes in liver biochemistry during methotrexate use for inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 105, no. 7, pp. 1620–1626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Goyal, J. S. Hyams, T. Lerer et al., “Liver enzyme elevations within three months of diagnosis of inflammatory bowel disease and likelihood of liver disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 20, no. 8, pp. 1341–1345, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. P. L. Valentino, P. C. Church, P. S. Shah et al., “Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis,” Inflammatory Bowel Diseases, vol. 20, no. 1, pp. 47–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Sotoudehmanesh, B. Anvari, M. Akhlaghi, S. Shahraeeni, and S. Kolahdoozan, “Methotrexate hepatotoxicity in patients with rheumatoid arthritis,” Middle East Journal of Digestive Diseases, vol. 2, no. 2, pp. 104–109, 2010. View at Google Scholar
  97. M. A. M. Berends, J. Snoek, E. M. G. J. de Jong et al., “Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 5, pp. 805–811, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. Q. E. Whiting-O'Keefe, K. H. Fye, and K. D. Sack, “Methotrexate and histologic hepatic abnormalities: a meta-analysis,” The American Journal of Medicine, vol. 90, no. 6, pp. 711–716, 1991. View at Publisher · View at Google Scholar · View at Scopus
  99. M. F. Dawwas and G. P. Aithal, “End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome,” Alimentary Pharmacology & Therapeutics, vol. 40, no. 8, pp. 938–948, 2014. View at Publisher · View at Google Scholar
  100. S. Kevat, M. Ahern, and P. Hall, “Hepatotoxicity of methotrexate in rheumatic diseases,” Medical Toxicology and Adverse Drug Experience, vol. 3, no. 3, pp. 197–208, 1988. View at Publisher · View at Google Scholar · View at Scopus
  101. M.-H. Lee, I. Hong, M. Kim et al., “Gene expression profiles of murine fatty liver induced by the administration of methotrexate,” Toxicology, vol. 249, no. 1, pp. 75–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Saphner, S. Triest-Robertson, H. Li, and P. Holzman, “The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer,” Cancer, vol. 115, no. 14, pp. 3189–3195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Murata, Y. Ogawa, T. Saibara et al., “Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients,” Oncology Reports, vol. 7, no. 6, pp. 1299–1304, 2000. View at Google Scholar · View at Scopus
  104. T. Ohnishi, Y. Ogawa, T. Saibara et al., “CYP17 polymorphism and tamoxifen-induced hepatic steatosis,” Hepatology Research, vol. 33, no. 2, pp. 178–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. P. R. Powell-Jackson, J. M. Tredger, and R. Williams, “Hepatotoxicity to sodium valproate: a review,” Gut, vol. 25, no. 6, pp. 673–681, 1984. View at Publisher · View at Google Scholar · View at Scopus
  106. F. E. Dreifuss, N. Santilli, D. H. Langer, K. P. Sweeney, K. A. Moline, and K. B. Menander, “Valproic acid hepatic fatalities: a retrospective review,” Neurology, vol. 37, no. 3, pp. 379–385, 1987. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Scheffner, I. Rauterberg-Ruland, W. Kochen, and W. J. Hofmann, “Fatal liver failure in 16 children with valproate therapy,” Epilepsia, vol. 29, no. 5, pp. 530–542, 1988. View at Publisher · View at Google Scholar · View at Scopus
  108. M. M. Schmid, R. W. Freudenmann, F. Keller et al., “Non-fatal and fatal liver failure associated with valproic acid,” Pharmacopsychiatry, vol. 46, no. 2, pp. 63–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. M. F. B. Silva, C. C. P. Aires, P. B. M. Luis et al., “Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review,” Journal of Inherited Metabolic Disease, vol. 31, no. 2, pp. 205–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. H. J. Zimmerman and K. G. Ishak, “Valproate induced hepatic injury: analyses of 23 fatal cases,” Hepatology, vol. 2, no. 5, pp. 591–597, 1982. View at Google Scholar · View at Scopus
  111. V. Belcastro, C. D'Egidio, P. Striano, and A. Verrotti, “Metabolic and endocrine effects of valproic acid chronic treatment,” Epilepsy Research, vol. 107, no. 1-2, pp. 1–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. G. J. Luef, M. Waldmann, W. Sturm et al., “Valproate therapy and nonalcoholic fatty liver disease,” Annals of Neurology, vol. 55, no. 5, pp. 729–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. L.-F. Zhang, L.-S. Liu, X.-M. Chu et al., “Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats,” Acta Pharmacologica Sinica, vol. 35, no. 3, pp. 363–372, 2014. View at Publisher · View at Google Scholar
  114. M. F. B. Silva, J. P. N. Ruiter, L. IJlst et al., “Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites,” Analytical Biochemistry, vol. 290, no. 1, pp. 60–67, 2001. View at Publisher · View at Google Scholar · View at Scopus
  115. C. C. P. Aires, L. IJlst, F. Stet et al., “Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis,” Biochemical Pharmacology, vol. 79, no. 5, pp. 792–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. I. Mannaerts, N. R. Nuytten, V. Rogiers, K. Vanderkerken, L. A. Van Grunsven, and A. Geerts, “Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo,” Hepatology, vol. 51, no. 2, pp. 603–614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,” The Journal of the American Medical Association, vol. 283, no. 1, pp. 74–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. J. C. Price and C. L. Thio, “Liver disease in the HIV-infected individual,” Clinical Gastroenterology and Hepatology, vol. 8, no. 12, pp. 1002–1012, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Gardner, P. A. Hall, P. F. Chinnery, and B. A. I. Payne, “HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies,” Toxicologic Pathology, vol. 42, no. 5, pp. 811–822, 2013. View at Publisher · View at Google Scholar
  120. N. Crum-Cianflone, A. Dilay, G. Collins et al., “Nonalcoholic fatty liver disease among HIV-infected persons,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 5, pp. 464–473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. G. Guaraldi, N. Squillace, C. Stentarelli et al., “Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors,” Clinical Infectious Diseases, vol. 47, no. 2, pp. 250–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Grinspoon and A. Carr, “Cardiovascular risk and body-fat abnormalities in HIV-infected adults,” The New England Journal of Medicine, vol. 352, no. 1, pp. 48–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Sundar, M. Suarez, P. E. Banogon, and J. M. Shapiro, “Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature,” Critical Care Medicine, vol. 25, no. 8, pp. 1425–1430, 1997. View at Publisher · View at Google Scholar · View at Scopus
  124. M. A. Akhtar, K. Mathieson, B. Arey et al., “Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 12, pp. 1194–1204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. J.-P. Duong van Huyen, A. Landau, C. Piketty et al., “Toxic effects of nucleoside reverse transcriptase inhibitors on the liver: value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy,” The American Journal of Clinical Pathology, vol. 119, no. 4, pp. 546–555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. J.-P. D. van Huyen, D. Batisse, D. Heudes et al., “Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients,” Modern Pathology, vol. 19, no. 10, pp. 1277–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. M. V. Stankov, D. Panayotova-Dimitrova, M. Leverkus et al., “Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation,” AIDS, vol. 26, no. 16, pp. 1995–2006, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Igoudjil, J. Massart, K. Begriche, V. Descatoire, M.-A. Robin, and B. Fromenty, “High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes,” Toxicology in Vitro, vol. 22, no. 4, pp. 887–898, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. A. B. Benson III, A. P. Venook, T. Bekaii-Saab et al., “Colon cancer, version 3.2014,” Journal of the National Comprehensive Cancer Network, vol. 12, no. 7, pp. 1028–1059, 2014. View at Google Scholar
  130. J.-N. Vauthey, T. M. Pawlik, D. Ribero et al., “Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 2065–2072, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. C. G. Moertel, T. R. Fleming, J. S. Macdonald, D. G. Haller, and J. A. Laurie, “Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy,” Journal of Clinical Oncology, vol. 11, no. 12, pp. 2386–2390, 1993. View at Google Scholar · View at Scopus
  132. P. D. Peppercorn, R. H. Reznek, P. Wilson, M. L. Slevin, and R. K. Gupta, “Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer,” British Journal of Cancer, vol. 77, no. 11, pp. 2008–2011, 1998. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Miyake, K. Hayakawa, M. Nishino, T. Morimoto, and S. Mukaihara, “Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer,” Academic Radiology, vol. 12, no. 6, pp. 722–727, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. C. H. C. Pilgrim, K. Brettingham-Moore, A. Pham et al., “mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury,” HPB, vol. 13, no. 11, pp. 811–816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. D. McWhirter, N. Kitteringham, R. P. Jones, H. Malik, K. Park, and D. Palmer, “Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes,” Critical Reviews in Oncology/Hematology, vol. 88, no. 2, pp. 404–415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. H. Zhang, J. M. Barceló, B. Lee et al., “Human mitochondrial topoisomerase I,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10608–10613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Bower, C. Wunderlich, R. Brown, C. R. Scoggins, K. M. McMasters, and R. C. G. Martin, “Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis,” American Journal of Surgery, vol. 205, no. 6, pp. 685–690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. E. Parkin, D. A. O'Reilly, R. Adam et al., “The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy,” HPB, vol. 15, no. 6, pp. 463–472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. E. Parkin, D. A. O'Reilly, R. Adam et al., “Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy,” European Journal of Surgical Oncology, vol. 40, no. 11, pp. 1436–1444, 2014. View at Google Scholar
  140. C. Reissfelder, K. Brand, J. Sobiegalla et al., “Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases,” Surgery, vol. 155, no. 2, pp. 245–254, 2014. View at Publisher · View at Google Scholar · View at Scopus